Prognostic and predictive factors in prostate cancer: Historical perspectives and recent international consensus initiatives
- 1 May 2005
- journal article
- review article
- Published by Taylor & Francis in Scandinavian Journal of Urology and Nephrology
- Vol. 39 (sup216) , 8-19
Abstract
An understanding of prognosis in cancer medicine is important for patient care, research and cancer control programs. In prostate cancer, prognostic (predictive) factors are particularly important given the marked heterogeneity of this disease at clinical, morphologic and biomolecular levels. Clinical stage and histologic grade have historically played major roles in defining heterogeneity in prostate cancer. More recently, serum prostate-specific antigen measurement has assumed a significant prognostic role. Over the last two decades there has been an explosion of research into biomarkers, many of which have been purported to have prognostic significance. In this paper we present an overview of the various consensus initiatives that have transpired over the last dozen years. Criteria for evaluating prognostic factors and classifications of predictive factors have emerged that have proven useful and advanced our understanding of the biology of prostate cancer. The results of these consensus initiatives form a foundation on which the current international consultation on prognosis (prediction) in prostate cancer is built. Advances in our understanding of the new and promising prognostic factors will require a more rigorous evidence-based approach to the analysis of published studies. Furthermore, appropriate mathematical models for the analysis of the multiple factors that influence a prognostic system will have to be employed.Keywords
This publication has 22 references indexed in Scilit:
- AJCC Cancer Staging Manual2002
- Prognostic Factors in Prostate CancerArchives of Pathology & Laboratory Medicine, 2000
- Post-treatment PSA ≤0.2 ng/ml defines disease freedom after radiotherapy for prostate cancer using modern techniquesUrology, 1999
- PSA decline is an independent prognostic marker in hormonally treated prostate cancer.European Urology, 1999
- The relationship between prognostic and predictive factors in the management of breast cancerBreast Cancer Research and Treatment, 1998
- Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomyUrology, 1997
- Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: the basis for an adjuvant therapy trial.Journal of Clinical Oncology, 1997
- Early Androgen Ablation for Stage D1 (N1 to N3, M0) Prostate Cancer: Prognostic Variables and OutcomeJournal of Urology, 1994
- Prediction of Prognosis for Prostatic Adenocarcinoma by Combined Histological Grading and Clinical StagingJournal of Urology, 1974
- CARCINOMA OF THE PROSTATEThe Lancet, 1934